Harvest Fund Management Co. Ltd Sells 43,134 Shares of Elanco Animal Health Incorporated $ELAN

Harvest Fund Management Co. Ltd lessened its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 72.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,183 shares of the company’s stock after selling 43,134 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Elanco Animal Health were worth $366,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Huntington National Bank boosted its position in Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares during the period. Root Financial Partners LLC boosted its position in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares during the period. Torren Management LLC bought a new position in Elanco Animal Health during the fourth quarter worth about $46,000. Fifth Third Bancorp boosted its position in Elanco Animal Health by 3,018.3% during the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after purchasing an additional 2,807 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in Elanco Animal Health by 43.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after purchasing an additional 938 shares during the period. Institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on ELAN shares. JPMorgan Chase & Co. increased their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. KeyCorp increased their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Morgan Stanley increased their target price on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Price Performance

ELAN stock opened at $23.61 on Friday. The firm has a 50 day moving average of $22.88 and a 200-day moving average of $23.39. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12 month low of $13.15 and a 12 month high of $27.72. The firm has a market capitalization of $11.79 billion, a P/E ratio of -47.22, a price-to-earnings-growth ratio of 1.55 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same period last year, the business earned $0.37 earnings per share. Elanco Animal Health’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by company insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.